Intuitive Surgical Q4 Earnings Beat Street, Expects Lower Gross Margin In FY22

Loading...
Loading...

Intuitive Surgical Inc ISRG reported Q4 adjusted EPS of $1.30, slightly ahead of the consensus of $1.28.

  • It reported revenues of $1.55 billion, +17% Y/Y, marginally ahead of Wall Street estimate of $1.52 billion, consistent with the preliminary results posted earlier this month.
  • The sales growth was driven by growth in da Vinci procedure volume and system placements.
  • Worldwide da Vinci procedures increased approximately 19% Y/Y, driven primarily by growth in U.S. general surgery procedures and growth in OUS markets.
  • The company held $8.6 billion in cash and equivalents at the end of Q4.
  • According to the Q4 conference call, the Q4 system average selling prices were $1.45 million, similar to $1.43 million last year and lower than $1.57 million last quarter. 
  • Instrument and accessory revenue per procedure were approximately $1,940 per procedure compared with $1,900 per procedure in Q3 FY21 and down 6% from $2,060 realized a year ago.
  • Pro forma gross margin of 70.1% was lower than 71.3% in Q3 FY21, primarily due to manufacturing inefficiencies and higher logistics costs, lower system ASPs, and a higher mix of systems revenue. 
  • Guidance: During 2022, Intuitive Surgical anticipates procedure growth of 11% - 15%, the lower end of the range assumes ongoing COVID pressure and hospital staffing shortages.
  • The company expects a slightly lower gross profit margin in FY22 than 71.2% in FY21, reflecting higher fixed costs and the impact of higher supply chain costs.
  • Price Action: ISRG shares are down 5.03% at $278.00 during the premarket session on the last check Friday.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...